Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman Says Biosimilar Pathway Will Push Applicants To BLA

Executive Summary

The outgoing chairman of the House Energy and Commerce Committee said the new abbreviated biosimilar pathway FDA is now formulating likely will not attract many applicants.

You may also be interested in...



Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?

IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.

Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway

Biosimilar products are not intended to be stand-alone development programs, agency stresses, noting that early analytical data can allow for more targeted clinical trials later.

Biosimilar Interchangeability: Stakeholders Want More FDA Guidance, Fewer Hurdles

The limited discussion of interchangeability in FDA’s initial biosimilar draft guidances has left some stakeholders clamoring for more details. Others say the agency’s demand for a “higher standard” of evidence to show interchangeability is misplaced and will inhibit use of the 351(k) pathway.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel